---
title: "Arogo Capital Acquisition | 10-Q: FY2025 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273880419.md"
datetime: "2026-01-27T18:26:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273880419.md)
  - [en](https://longbridge.com/en/news/273880419.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273880419.md)
---

# Arogo Capital Acquisition | 10-Q: FY2025 Q1 Revenue: USD 0

Revenue: As of FY2025 Q1, the actual value is USD 0.

EPS: As of FY2025 Q1, the actual value is USD -0.07.

EBIT: As of FY2025 Q1, the actual value is USD -298.36 K.

Arogo Capital Acquisition Corp. is a blank check company that has not generated any operating revenues as of March 31, 2025, with its activities focused on formation and evaluating business combination targets.

#### Operational Metrics

-   **Net Loss**: The company reported a net loss of -$104,395 for the three months ended March 31, 2025, which is an improvement from a net loss of -$188,723 for the three months ended March 31, 2024.
-   **Formation and Operating Costs**: These costs decreased to $171,379 for the three months ended March 31, 2025, from $358,992 for the same period in 2024.
-   **Franchise Tax**: Franchise tax expense was $30,000 for the three months ended March 31, 2025, compared to $35,600 for the prior year’s comparable period.
-   **Loss from Operation**: The loss from operation was -$201,379 for the three months ended March 31, 2025, down from -$394,592 in the prior year.
-   **Interest Earned**: Interest earned was $2 for the three months ended March 31, 2025, compared to $1 for the same period in 2024.
-   **Unrealized Gain/Loss on Cash Held in Trust Account**: The company reported an unrealized gain of $96,982 for the three months ended March 31, 2025, a decrease from $251,129 in the same period in 2024.
-   **Working Capital Deficit**: The working capital deficit improved to -$6,385,167 as of March 31, 2025, from -$25,596,951 as of December 31, 2024.
-   **Total Stockholders’ Deficit**: The total stockholders’ deficit increased to -$9,779,066 as of March 31, 2025, from -$9,406,952 as of December 31, 2024.

#### Cash Flow

-   **Cash at Period End**: Cash on hand was $52,755 as of March 31, 2025, down from $122,013 as of December 31, 2024.
-   **Cash held in Trust Account**: Cash held in the Trust Account was $285,779 as of March 31, 2025, a significant decrease from $20,262,514 as of December 31, 2024.
-   **Net Cash Used in Operating Activities**: Net cash used in operating activities for the three months ended March 31, 2025, was -$69,260, an increase from -$40,850 for the same period in 2024.
-   **Net Cash Used in Investing Activities**: Net cash used in investing activities was -$20,073,718 for the three months ended March 31, 2025, compared to -$79,750 for the same period in 2024, primarily due to redemptions.
-   **Net Cash Provided by Financing Activities**: Net cash provided by financing activities was $20,073,720 for the three months ended March 31, 2025, significantly higher than $120,001 for the same period in 2024, driven by redemption of common stock.

#### Future Outlook and Strategy

Arogo Capital Acquisition Corp. has until June 29, 2026, to complete its initial business combination and is currently pursuing a merger with Bangkok Tellink Co., Ltd., a Thailand-based telecommunications and IoT solutions provider. The company faces substantial doubt about its ability to continue as a going concern if a business combination is not consummated within the prescribed period, following its delisting from Nasdaq and trading on the OTC Pink Market. Arogo Capital Acquisition Corp. intends to raise additional funds for working capital and potential business combinations.

### Related Stocks

- [AOGO.US](https://longbridge.com/en/quote/AOGO.US.md)

## Related News & Research

- [Fiserv Investor Day Sets AI, Clover Roadmap to Revive Growth and Top $12 EPS](https://longbridge.com/en/news/286656225.md)
- [Dear Future SpaceX (SPCX) Stock Fans, Mark Your Calendars for June 12](https://longbridge.com/en/news/286809659.md)
- [Eli Lilly Retatrutide 12 Mg Achieved 30.3% Average Weight Loss At 104 Weeks In Extension](https://longbridge.com/en/news/287203984.md)
- [Celestica Director Sold Shares Worth Over $1.3M](https://longbridge.com/en/news/287130203.md)
- [FOCUS-As cocoa prices melt down, real chocolate is making a comeback](https://longbridge.com/en/news/287091302.md)